The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma
Open accessAbstract
BACKGROUND: Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial. METHODS: We evaluated outcomes in 2001 patients with primary cutaneous melanomas randomly assigned to undergo wide excision and nodal observation, with lymphadenectomy for nodal relapse (observation group), or wide excision and sentinel-node biopsy, with immediate lymphadenectomy for nodal metastases detected on biopsy (biopsy group). Results No significant treatment-related difference in the 10-year melanoma-specific survival rate was seen in the overall study population (20.8% with and 79.2% without nodal metastases). Mean (± SE) 10-year disease-free survival rates were significantly improved in the biopsy group, as compared with the observation group, among patients with intermediate-thickness melanomas, defined as 1.20 to 3.50 mm (71.3 ± 1.8% vs. 64.7 ± 2.3%; hazard ratio for recurrence or metastasis, 0.76; P=0.01), and those with thick melanomas, defined as >3.50 mm (50.7 ± 4.0% vs. 40.5 ± 4.7%; hazard ratio, 0.70; P=0.03). Among patients with intermediate-thickness melanomas, the 10-year melanoma-specific survival rate was 62.1 ± 4.8% among those with metastasis versus 85.1 ± 1.5% for those without metastasis (hazard ratio for death from melanoma, 3.09; P<0.001); among patients with thick melanomas, the respective rates were 48.0 ± 7.0% and 64.6 ± 4.9% (hazard ratio, 1.75; P=0.03). Biopsy-based management improved the 10-year rate of distant disease-free survival (hazard ratio for distant metastasis, 0.62; P=0.02) and the 10-year rate of melanoma-specific survival (hazard ratio for death from melanoma, 0.56; P=0.006) for patients with intermediate-thickness melanomas and nodal metastases. Accelerated-failure-time latent-subgroup analysis was performed to account for the fact that nodal status was initially known only in the biopsy group, and a significant treatment benefit persisted. CONCLUSIONS: Biopsy-based staging of intermediate-thickness or thick primary melanomas provides important prognostic information and identifies patients with nodal metastases who may benefit from immediate complete lymphadenectomy. Biopsy-based management prolongs disease-free survival for all patients and prolongs distant disease-free survival and melanoma-specific survival for patients with nodal metastases from intermediate-thickness melanomas. (Funded by the National Cancer Institute, National Institutes of Health, and the Australia and New Zealand Melanoma Trials Group; ClinicalTrials.gov number, NCT00275496.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,602
Self-citationTechnical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma
Morton, D. L. (1992) · Archives of Surgery · doi:10.1001/archsurg.1992.01420040034005 · Cited by 4,371
Self-citationSentinel-Node Biopsy or Nodal Observation in Melanoma
Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Elashoff, R., Essner, R., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060992 · Cited by 1,824
Self-citationMorton, D. L., Cochran, A. J., Thompson, J. F., Elashoff, R., Essner, R., Glass, E. C., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000181092.50141.fa · Cited by 715
Self-citationExcision Margins in High-Risk Malignant Melanoma
Thomas, J. M., Newton‐Bishop, J., A’Hern, R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030681 · Cited by 504
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Ding, S., Byrd, D. R., Cascinelli, N., Cochran, A. J., Coit, D. G., Eggermont, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1627 · Cited by 410
Self-citationEggermont, A. M. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H. J., Marsden, J., Punt, C. J. A., Salès, F., Dummer, R., Robert, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3799 · Cited by 285
Cochran, A. J., Morton, D. L., Stern, S., Lana, A. M. A., Essner, R., & Wen, D.-R. (2001) · Modern Pathology · doi:10.1038/modpathol.3880358 · Cited by 165
Self-citationSPANIDOU, E., & Petrakis, N. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92231-3 · Cited by 154
Altstein, L. L., & Li, G. (2013) · Biometrics · doi:10.1111/j.1541-0420.2012.01818.x · Cited by 50
Cited by
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationGershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
Self-citationSchadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K. G., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,488
Ferroptosis: Mechanisms and links with diseases
Yan, H.-F., Zou, T., Tuo, Q.-Z., Xu, S., Li, H., Belaidi, A. A., & Lei, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00428-9 · Cited by 1,471
“Melanoma usually metastases to lymph nodes before forming distant metastases due to the low cell survival rate in the blood, which is one of the most important predictors of distant metastasis and death in patients with cutaneous melanomas.(181,182) It is recently shown that the lymphatic environment protects metastas…”
BackgroundCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Faries, M. B., Thompson, J. F., Cochran, A. J., Andtbacka, R. H., Mozzillo, N., Zager, J. S., Jahkola, T., Bowles, T. L., Testori, A., Beitsch, P. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613210 · Cited by 1,414
Self-citationShain, A. H., & Bastian, B. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.37 · Cited by 896
Lymph protects metastasizing melanoma cells from ferroptosis
Ubellacker, J. M., Tasdogan, A., Ramesh, V., Shen, B., Mitchell, E. C., Martin-Sandoval, M. S., Gu, Z., McCormick, M. L., Durham, A. B., Spitz, D. R., et al. (2020) · Nature · doi:10.1038/s41586-020-2623-z · Cited by 896
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Guidelines of care for the management of primary cutaneous melanoma
Swetter, S. M., Tsao, H., Bichakjian, C. K., Curiel-Lewandrowski, C., Elder, D. E., Gershenwald, J. E., Guild, V., Grant-Kels, J. M., Halpern, A. C., Johnson, T. M., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.08.055 · Cited by 727
Self-citationLeiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., Sunderkötter, C., Kaatz, M., Schulte, K.-W., Lehmann, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00141-8 · Cited by 707
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., & Keilholz, U. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz411 · Cited by 617
Schadendorf, D., Fisher, D. E., Garbe, C., Gershenwald, J. E., Grob, J.-J., Halpern, A., Herlyn, M., Marchetti, M. A., McArthur, G., Ribas, A., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.3 · Cited by 613
Keung, E. Z., & Gershenwald, J. E. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1489246 · Cited by 593
Pereira, E. R., Kedrin, D., Seano, G., Gautier, O., Meijer, E. F. J., Jones, D., Chin, S.-M., Kitahara, S., Bouta, E. M., Chang, J., et al. (2018) · Science · doi:10.1126/science.aal3622 · Cited by 477
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy
Fransen, M. F., Schoonderwoerd, M., Knopf, P., Camps, M. G. M., Hawinkels, L. J. A. C., Kneilling, M., van Hall, T., & Ossendorp, F. (2018) · JCI Insight · doi:10.1172/jci.insight.124507 · Cited by 427
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.008 · Cited by 329
Wong, S. L., Faries, M. B., Kennedy, E. B., Agarwala, S. S., Akhurst, T. J., Ariyan, C., Balch, C. M., Berman, B. S., Cochran, A., Delman, K. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7724 · Cited by 284
Self-citationEuropean consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Basset-Seguin, N., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.018 · Cited by 283
The wound inflammatory response exacerbates growth of pre‐neoplastic cells and progression to cancer
Antonio, N., Bønnelykke‐Behrndtz, M. L., Ward, L. C., Collin, J., Christensen, I. J., Steiniche, T., Schmidt, H., Feng, Y., & Martin, P. (2015) · The EMBO Journal · doi:10.15252/embj.201490147 · Cited by 280
Recent progress in the treatment and prevention of cancer‐related lymphedema
Shaitelman, S. F., Cromwell, K. D., Rasmussen, J. C., Stout, N. L., Armer, J. M., Lasinski, B. B., & Cormier, J. N. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21253 · Cited by 255
Ecker, B. L., Kaur, A., Douglass, S. M., Webster, M. R., Almeida, F. V., Marino, G. E., Sinnamon, A. J., Neuwirth, M. G., Alicea, G. M., Ndoye, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0168 · Cited by 153
“Yet, the lack of survival benefit following lymphadenectomy in patients with melanoma has inspired the alternate view that lymphatic and visceral metastases develop independently (25).”
BackgroundSelf-citationIdentification of Cancer Stem Cell Subpopulations in Head and Neck Metastatic Malignant Melanoma
Yoganandarajah, V., Patel, J., van Schaijik, B., Bockett, N., Brasch, H. D., Paterson, E., Sim, D., Davis, P. F., Roth, I. M., Itinteang, T., et al. (2020) · Cells · doi:10.3390/cells9020324 · Cited by 26
Metadata
- Authors
- Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., Puleo, C. A., Coventry, B. J., Kashani-Sabet, M., Smithers, B. M., Paul, E., Kraybill, W. G., McKinnon, J. G., Wang, H.-J., Elashoff, R., & Faries, M. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-13
- Volume
- 370
- Issue
- 7
- Pages
- 599-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2145956339
- Cited by
- 1,484
- References
- 11
- FWCI
- 67.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.